Latest action: Ordered to be Reported by the Yeas and Nays: 44 - 0.
Committee has approved the bill (usually with amendments) and sent it back to the full chamber.
The committee voted to send the bill to the floor of the full chamber. The Speaker of the House schedules a floor vote.
Next: Passed One Chamber
The other chamber (Senate or House) repeats the committee + floor-vote process
Updates FDA drug approval processes and modernizes regulatory requirements for pharmaceutical companies.
The problem
FDA regulations haven't kept pace with modern drug development technology and scientific advances. Current processes may slow patient access to new medicines.
The proposal
Changes FDA approval timelines, updates drug testing standards, streamlines review procedures, and adjusts regulatory requirements for pharmaceutical companies.
The impact
Drug companies face different rules. Patients may get new medicines faster. FDA staff handle different workloads. Healthcare system adapts to new approval processes.
Streamlined approval could get new medicines to patients more quickly. This helps people with serious diseases access treatment sooner. Speed matters for patients waiting for cures.
Modernized processes may lower expenses for drug manufacturers. Lower costs could reduce medicine prices eventually. Companies might invest more in new drug research.
New regulations reflect current scientific knowledge and technology. Modern testing methods are often more accurate. This aligns FDA rules with how science actually works today.
The committee vote was 44-0, showing agreement across parties. Strong support suggests broad agreement the FDA needs updates. Unified support increases chances of successful implementation.
Faster approval might mean less testing time before medicines reach patients. Rushing could miss rare side effects discovered later. Patient safety requires sufficient evidence gathering.
Streamlined processes might reduce FDA's ability to catch problems. Less review time means fewer chances to identify issues. Regulatory oversight is important protection for public health.
Without an official summary, exact changes are uncertain. Citizens don't know specifically what's being modified. Transparency about rule changes helps public understand impact.
Changing processes requires staff retraining and system updates. Agency might struggle with implementation costs. New workflows could create initial disruptions.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.